Bristol Myers Squibb (NYSE:BMY) Releases Earnings Results, Misses Estimates By $0.39 EPS

Bristol Myers Squibb (NYSE:BMY) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39), FiscalAI reports. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the prior year, the business earned $1.67 earnings per share. Bristol Myers Squibb’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb updated its FY 2026 guidance to 6.050-6.350 EPS.

Here are the key takeaways from Bristol Myers Squibb’s conference call:

• Growth portfolio momentum — Growth portfolio revenue rose ~15% in Q4 and 17% for FY2025, with Opdualag, Breyanzi and Camzyos each >$1B and Reblozyl >$2B, and those newer products nearly offset a ~ $4B decline in the legacy portfolio.
• Data-rich pipeline in 2026 — BMS expects top-line registrational readouts for six potential new products and >10 pivotal readouts this year (examples: Milvexian, Admilparant, Iberdomide, Mezigdomide, RYZ101, Sotyktu and Cobenfy extensions), concentrated in H2 and positioned as key near-term catalysts.
• 2026 financial guide — Company guided 2026 revenue of $46.0–$47.5B, gross margin ~69%–70%, operating expenses ~ $16.3B and adjusted EPS of $6.05–$6.35, while noting continued reinvestment into launches and selected development programs.
• Eliquis transition risk — Eliquis is expected to grow 10%–15% in 2026 (helped by pricing/contract changes), but management anticipates a $1.5–$2.0B step-down in 2027 driven by generic entry and EU patent expirations late‑2026.
• Cost, cash and capital allocation — BMS delivered ~ $1B of a $2B productivity target in 2025, expects the remaining $1B across 2026–27, holds ~ $11B cash/marketable securities, completed a targeted $10B debt paydown and plans continued BD plus dividend returns.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY traded up $2.14 on Friday, reaching $61.66. 8,001,588 shares of the company were exchanged, compared to its average volume of 13,187,125. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $63.33. The company has a 50-day moving average of $54.08 and a 200-day moving average of $48.92. The firm has a market cap of $125.52 billion, a price-to-earnings ratio of 20.82, a price-to-earnings-growth ratio of 0.18 and a beta of 0.29.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. The ex-dividend date was Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is presently 85.14%.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of institutional investors and hedge funds have recently modified their holdings of the company. Binnacle Investments Inc raised its holdings in Bristol Myers Squibb by 17.0% during the second quarter. Binnacle Investments Inc now owns 1,801 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 262 shares during the last quarter. E Fund Management Co. Ltd. boosted its position in shares of Bristol Myers Squibb by 2.6% in the 2nd quarter. E Fund Management Co. Ltd. now owns 10,409 shares of the biopharmaceutical company’s stock worth $482,000 after buying an additional 267 shares in the last quarter. New England Asset Management Inc. grew its stake in Bristol Myers Squibb by 0.8% in the 3rd quarter. New England Asset Management Inc. now owns 40,036 shares of the biopharmaceutical company’s stock valued at $1,806,000 after acquiring an additional 315 shares during the last quarter. Keystone Financial Group increased its holdings in Bristol Myers Squibb by 4.9% during the 3rd quarter. Keystone Financial Group now owns 7,136 shares of the biopharmaceutical company’s stock valued at $322,000 after acquiring an additional 332 shares in the last quarter. Finally, Financial Advisors Network Inc. raised its position in Bristol Myers Squibb by 7.7% during the second quarter. Financial Advisors Network Inc. now owns 5,041 shares of the biopharmaceutical company’s stock worth $233,000 after acquiring an additional 359 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Company raised the 2026 outlook and guided revenue above Street expectations, citing strategic moves (including an Eliquis pricing change) that management expects will drive higher sales next year — a key reason investors are buying the stock. Reuters: Bristol Myers forecasts upbeat 2026
• Positive Sentiment: Q4 revenue beat estimates as the Growth Portfolio (immuno‑oncology and newer products) showed strong gains, offsetting declines in older drugs — the revenue beat is supporting the rally. Zacks: BMY stock up as Q4 earnings and revenues beat estimates
• Positive Sentiment: Management (CEO) highlighted what it called the strongest product pipeline in years and emphasized upcoming catalysts — investor confidence in future approvals/commercial launches is boosting sentiment. YouTube: Bristol Myers Squibb CEO interview
• Positive Sentiment: Company is pushing new growth engines and expanding manufacturing/partnering arrangements (noted in analyst summaries), which lowers execution risk for upcoming product rollouts. TipRanks: Bristol‑Myers bets on new growth engines
• Neutral Sentiment: Earnings per share headlines are mixed: non‑GAAP EPS of $1.26 beat some consensus models (e.g., Zacks), but EPS is down year‑over‑year — this creates nuance in the beat/miss narrative. Seeking Alpha: Non‑GAAP EPS and revenue summary
• Neutral Sentiment: Macro/market noise (weekly jobless claims print) may be influencing broad market moves, adding volatility but not directly linked to BMY’s fundamentals. Zacks: Weekly jobless claims
• Negative Sentiment: Legacy products continue to decline and overall EPS remains below year‑ago levels, which is a reminder that near‑term growth hinges on successful ramp of newer drugs and the payoff from pricing/portfolio moves. WSJ: Revenue ticks up on immuno‑oncology growth

Analyst Ratings Changes

A number of analysts have recently commented on BMY shares. Morgan Stanley reiterated an “underweight” rating on shares of Bristol Myers Squibb in a research report on Friday. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $57.00 price target (up previously from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Scotiabank reaffirmed a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Finally, Leerink Partners increased their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Eight equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $58.73.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.